These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2116315)

  • 1. Tissue plasminogen activator levels in different types of polycythemia.
    Cohen AM; Gelvan A; Kadouri A; Creter D; Djaldetti M
    Eur J Haematol; 1990 Jul; 45(1):48-51. PubMed ID: 2116315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.
    Cancelas JA; García-Avello A; García-Frade LJ
    Thromb Res; 1994 Sep; 75(5):513-20. PubMed ID: 7992252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboembolic complications of polycythemia: polycythemia vera versus smokers' polycythemia.
    Schwarcz TH; Hogan LA; Endean ED; Roitman IT; Kazmers A; Hyde GL
    J Vasc Surg; 1993 Mar; 17(3):518-22; discussion 522-3. PubMed ID: 8445747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
    Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M
    Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma homocysteine levels in 10 patients with polycythemia.
    Tonon G; Boyd K; Lecchi A; Lombardi R; Porcella A; Cattaneo M
    Haematologica; 1997; 82(3):343-4. PubMed ID: 9234587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum erythropoietin (ESF) titers in polycythemia.
    de Klerk G; Rosengarten PC; Vet RJ; Goudsmit R
    Blood; 1981 Dec; 58(6):1171-4. PubMed ID: 7306705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin radioimmunoassay in evaluating patients with polycythemia.
    Koeffler HP; Goldwasser E
    Ann Intern Med; 1981 Jan; 94(1):44-7. PubMed ID: 7447223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fibrinolytic system and proteins C and S in treated polycythaemia rubra vera.
    Wieczorek I; MacGregor IR; Prescott RJ; Ludlam CA
    Blood Coagul Fibrinolysis; 1992 Dec; 3(6):823-6. PubMed ID: 1489903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-Schönlein purpura.
    Besbas N; Erbay A; Saatçi U; Ozdemir S; Bakkaloglu A; Ozen S; Topaloglu R
    Clin Exp Rheumatol; 1998; 16(1):95-8. PubMed ID: 9543574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
    Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
    Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids.
    Petersen KR; Kjems LL; Skouby SO; Andersen LF; Jespersen J
    Metabolism; 1996 Jul; 45(7):833-7. PubMed ID: 8692017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial natriuretic peptide in relative polycythemia and polycythemia vera.
    Cohen AM; Gelvan A; Winaver J; Kahna L; Floru S; Djaldetti M
    Haematologica; 1989; 74(4):351-3. PubMed ID: 2529200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selected parameters of hemostasis in patients with myeloproliferative neoplasms.
    Gadomska G; Rość D; Stankowska K; Boinska J; Ruszkowska-Ciastek B; Wieczór R
    Blood Coagul Fibrinolysis; 2014 Jul; 25(5):464-70. PubMed ID: 24509338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [T-PA and PAI-1 in lymphocytes of patients with chronic lymphoid leukemia].
    Kowalewska A; Rość D; Szadziewska-Kowalska D; Góralczyk K
    Pol Arch Med Wewn; 2006 Mar; 115(3):197-202. PubMed ID: 18468424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.
    Gordeuk VR; Key NS; Prchal JT
    Haematologica; 2019 Apr; 104(4):653-658. PubMed ID: 30872370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aquagenic pruritus in polycythemia vera: A cross-sectional study.
    Lelonek E; Matusiak Ł; Wróbel T; Szepietowski JC
    J Am Acad Dermatol; 2021 Jul; 85(1):211-213. PubMed ID: 29066270
    [No Abstract]   [Full Text] [Related]  

  • 17. Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood.
    Valen G; Eriksson E; Risberg B; Vaage J
    Eur J Cardiothorac Surg; 1994; 8(6):324-30. PubMed ID: 8086178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
    Leiper K; Croll A; Booth NA; Moore NR; Sinclair T; Bennett B
    J Clin Pathol; 1994 Mar; 47(3):214-7. PubMed ID: 8163691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic changes in plasma tissue plasminogen activator, plasminogen activator inhibitor-1 and beta-thromboglobulin content in ischemic stroke.
    Zhuang P; Wo D; Xu ZG; Wei W; Mao HM
    J Clin Neurosci; 2015 Jul; 22(7):1123-7. PubMed ID: 26002716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
    Jokaji H; Asakura H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
    Nihon Ronen Igakkai Zasshi; 1990 Nov; 27(6):699-705. PubMed ID: 2127812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.